blog | Braveheart Bio

Skip to content

Login

Login

Subscribe to our Newsletter

Go Back to Home

Go Back to Blog

IPOs, 2026, Braveheart Bio

Braveheart Bio (BRVE) Sets Terms for $300 Million IPO to Advance Next-Generation Therapy for Hypertrophic Cardiomyopathy

Eric Friedman

Jul 31, 2026, 1:41:24 PM

Braveheart Bio (NASDAQ: BRVE) has filed to raise approximately $300 million through an initial publi...

Subscribe to our Newsletter

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.

Copyright © 2025